Product image of Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19) supplied by GNH India

Menjugate

Active Ingredient:
N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19
Origin:
EU

Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19)

N. meningitidis Group C (Strain C11) oligosaccharide conjugated to Corynebacterium diphtheriae CRM197, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent disease caused by Neisseria meningitidis serogroup C in individuals at risk, such as infants, children, and adolescents.

GNH India supplies Menjugate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Gsk Vaccines S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Menjugate is a conjugate vaccine that targets meningococcal disease caused by serogroup C.

  • Infants: induction of protective antibodies against Neisseria meningitidis serogroup C.
  • Children and adolescents: booster protection to maintain immunity against serogroup C.
  • Adults at increased risk (e.g., travelers, outbreak settings): prevention of invasive meningococcal disease caused by serogroup C.

How It Works

  • Menjugate contains the polysaccharide capsule of Neisseria meningitidis group C covalently linked to the diphtheria toxoid CRM197. The conjugate is taken up by antigen‑presenting cells, processed, and presented to T cells, which stimulate B‑cell production of high‑affinity, class‑switched antibodies. These antibodies neutralize the bacterial capsule, providing active immunity against serogroup C infection.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: low‑grade temperature rise within 24‑48 hours.
  • Headache: transient headache post‑vaccination.
  • Fatigue: temporary tiredness.
  • Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurologic disorder with ascending weakness.
  • Seizures: uncommon neurologic event.
  • Severe hypotension: marked drop in blood pressure.
  • Persistent high fever: fever lasting more than 48 hours.
  • Severe local reaction: extensive necrosis or ulceration at the injection site.

Precautions & Warnings

Menjugate should be administered only after evaluating the individual's medical history.

  • Severe allergy: Do not vaccinate persons with a known severe hypersensitivity to any vaccine component.
  • Acute illness: Postpone vaccination in individuals with moderate or severe acute febrile illness.
  • Immunocompromised patients: Assess immune status as response may be reduced.
  • Blood product receipt: Delay vaccination for at least 3 months after receiving immunoglobulins or blood products.
  • Pregnancy and lactation: Use only if the potential benefit outweighs the potential risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccination may interact with other agents that affect the immune system.

Major Interactions (Avoid)

  • Live bacterial vaccines: avoid simultaneous administration to prevent interference with immune response.
  • Severe allergic reaction to a previous dose: contraindicated.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive therapy: may diminish vaccine efficacy; monitor antibody levels.
  • Antipyretics (e.g., acetaminophen, ibuprofen): can mask fever, a common post‑vaccination sign.
  • Blood products or immunoglobulins: may reduce immunogenicity if given within 3 months before or after vaccination.

Frequently Asked Questions

Menjugate is a conjugate vaccine indicated for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is administered to individuals at risk, including infants, children, adolescents, and adults traveling to endemic areas, to stimulate protective immunity against this specific meningococcal strain.

The active ingredient combines the polysaccharide capsule of meningococcus group C with the diphtheria toxoid CRM197. This conjugate is recognized by the immune system as a protein, prompting T‑cell help and the production of high‑affinity antibodies that specifically target the bacterial capsule, thereby preventing infection.

The dosing regimen for Menjugate is determined by the prescribing clinician based on the patient’s age, health status, and vaccination schedule. The healthcare professional will decide the number of doses, intervals, and any booster requirements according to national immunization guidelines.

Safety data for Menjugate in pregnancy and lactation are limited. The vaccine should only be administered when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances with the patient before vaccination.

To order Menjugate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Menjugate is a conjugate vaccine targeting serogroup C, whereas other meningococcal vaccines may be polysaccharide‑based or cover additional serogroups (A, W, Y, B). Conjugate vaccines like Menjugate generally induce stronger, longer‑lasting immunity and are suitable for younger children compared with polysaccharide formulations.

Menjugate must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If the cold chain is broken, the vaccine should not be used and must be returned to the supplier.

Menjugate is given as an intramuscular injection, typically into the deltoid muscle of the upper arm for older children and adults, or the anterolateral thigh for infants and young children. The injection is performed by a qualified healthcare professional using aseptic technique.

The most serious risks include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and rare neurologic events like seizures. Immediate medical attention is required if signs of a severe reaction appear, such as difficulty breathing, swelling of the face or throat, or rapid onset of weakness.

Menjugate should not be given to individuals with a documented severe hypersensitivity to any component of the vaccine, including the CRM197 protein. It is also contraindicated in persons who have experienced a severe allergic reaction to a previous dose of Menjugate.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT